Meredith Cook Sells 400 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $87.27, for a total transaction of $34,908.00. Following the transaction, the vice president owned 75,274 shares of the company’s stock, valued at $6,569,161.98. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Monday, October 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $90.09, for a total value of $36,036.00.
• On Friday, September 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $98.42, for a total value of $39,368.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $84.02 on Friday. The stock’s 50-day simple moving average is $92.77 and its two-hundred day simple moving average is $78.18. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $99.50. The firm has a market capitalization of $1.82 billion, a P/E ratio of -109.12 and a beta of 0.54. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter last year, the company posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on ANIP. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Piper Sandler restated an “overweight” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $99.29.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Global Alpha Capital Management Ltd. lifted its position in ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the last quarter. UBS Group AG increased its stake in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the period. Aberdeen Group plc increased its stake in shares of ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after buying an additional 181,134 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $32,992,000. Finally, Rubric Capital Management LP boosted its position in ANI Pharmaceuticals by 33.3% during the 3rd quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock valued at $31,457,000 after buying an additional 85,745 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.